ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

Safety and Efficacy of NBI-98854 in Pediatric Subjects With Tourette Syndrome

ClinicalTrials.gov ID: NCT03530293

Public ClinicalTrials.gov record NCT03530293. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 20, 2026, 1:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Evaluate the Safety and Efficacy of NBI-98854 in Pediatric Subjects With Tourette Syndrome

Study identification

NCT ID
NCT03530293
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Neurocrine Biosciences
Industry
Enrollment
81 participants

Conditions and interventions

Interventions

  • Placebo oral capsule Drug
  • Valbenazine Drug

Drug

Eligibility (public fields only)

Age range
6 Years to 17 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 16, 2018
Primary completion
Jul 15, 2019
Completion
Jul 15, 2019
Last update posted
May 16, 2022

2018 – 2019

United States locations

U.S. sites
48
U.S. states
22
U.S. cities
46
Facility City State ZIP Site status
Neuricrine Clinical Site Sun City Arizona 85351
Neurocrine Clinical Site Little Rock Arkansas 72205
Neurocrine Clinical Site Rogers Arkansas 72758
Neurocrine Clinical Site Anaheim California 92805
Neurocrine Clinical Site Fullerton California 92835
Neurocrine Clinical Site San Diego California 92108
Neurocrine Clinical Site Santa Ana California 92705
Neurocrine Clinical Site Pueblo Colorado 81003
Neurocrine Clinical Site Stamford Connecticut 06905
Neurocrine Clinical Site Washington D.C. District of Columbia 22207
Neurocrine Clinical Site Gulf Breeze Florida 32561
Neurocrine Clinical Site Hialeah Florida 33012
Neurocrine Clinical Site Miami Florida 33125
Neurocrine Clinical Site Miami Florida 33136
Neurocrine Clinical Site North Miami Florida 33161
Neurocrine Clinical Site Orlando Florida 32803
Neurocrine Clinical Site Palmetto Bay Florida 33157
Neurocrine Clinical Site Spring Hill Florida 34609
Neurocrine Clinical Site St. Petersburg Florida 33701
Neurocrine Clinical Site Tallahassee Florida 32308
Neurocrine Clinical Site Atlanta Georgia 30338
Neurocrine Clinical Site Fayetteville Georgia 30214
Neurocrine Clinical Site Savannah Georgia 31406
Neurocrine Clinical Site Chicago Illinois 60634
Neurocrine Clinical Site South Bend Indiana 46617
Neurocrine Clinical Site Boston Massachusetts 02114
Neurocrine Clinical Site Ann Arbor Michigan 48015
Neurocrine Clinical Site Bloomfield Hills Michigan 48302
Neurocrine Clinical Site West Bloomfield Michigan 48322
Neurocrine Clinical Site Lincoln Nebraska 68526
Neurocrine Clinical Site Nashua New Hampshire 03060
Neurocrine Clinical Site Cherry Hill New Jersey 08002
Neurocrine Clinical Site Mount Arlington New Jersey 07856
Neurocrine Clinical Site New York New York 10036
Neurocrine Clinical Site South Setauket New York 11720
Neurocrine Clinical Site Charlotte North Carolina 29141
Neurocrine Clinical Site Mason Ohio 45040
Neurocrine Clinical Site Oklahoma City Oklahoma 73112
Neurocrine Clinical Site Dallas Texas 75243
Neurocrine Clinical Site DeSoto Texas 75115
Neurocrine Clinical Site Houston Texas 77030
Neurocrine Clinical Site Houston Texas 77058
Neurocrine Clinical Site Irving Texas 75062
Neurocrine Clinical Site San Antonio Texas 78249
Neurocrine Clinical Site Charlottesville Virginia 22903
Neurocrine Clinical Site Bothell Washington 98011
Neurocrine Clinical Site Everett Washington 98201
Neurocrine Clinical Site Spokane Washington 99202

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03530293, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 16, 2022 · Synced May 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03530293 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →